The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project Experience
Abstract
Purpose: We reviewed data from all adjuvant NSABP breast cancer trials that tested regimens containing both doxorubicin (A) and cyclophosphamide (C) to characterize the incidence of subsequent acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Materials and Methods: Six complete NSABP trials have investigated AC regimens (B-15, B-16, B-18, B-22, B-23, and B-25). Six distinct AC regimens have been tested and are distinguished by differences in cyclophosphamide intensity and cumulative dose and by the presence or absence of mandated prophylactic support with growth factor and ciprofloxacin. In all regimens, A was given at 60 mg/m 2 q 21 days × 4. C was given as follows: 600 mg/m 2 q 21 days × 4 (“standard AC”); 1,200 mg 2 q 21 days × 2; 1,200 mg/m 2 q 21 days × 4; 2,400 mg/m 2 q 21 days × 2; and 2,400 mg/m 2 q 21 days × 4. Occurrence of AML/MDS was summarized by incidence per 1,000 patient-years at risk and by cumulative incidence. Rates were compared across regimens, by age, and by treatment with or without breast radiotherapy. Results: The incidence of AML/MDS was sharply elevated in the more intense regimens. In patients receiving two or four cycles of C at 2,400 mg/m 2 with granulocyte colony-stimulating factor (G-CSF) support, cumulative incidence of AML/MDS at 5 years was 1.01% (95% confidence interval [CI], 0.63% to 1.62%), compared with 0.21% (95% CI, 0.11% to 0.41%) for patients treated with standard AC. Patients who received breast radiotherapy experienced more secondary AML/MDS than those who did not (RR = 2.38, P= .006), and the data indicated that G-CSF does may possibly also be independently correlated with increased risk. Conclusion: AC regimens employing intensified doses of cyclophosphamide requiring G-CSF support were characterized by increased rates of subsequent AML/MDS, although the incidence of AML/MDS was small relative to that of breast cancer relapse. Breast radiotherapy appeared to be associated with an increased risk of AML/MDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,627
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, D. A. G., GRALNICK, H. R., & SULTAN, C. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-620 · Cited by 2,926
Overgaard, M., Hansen, P. S., Overgaard, J., Rose, C., Andersson, M., Bach, F., Kjaer, M., Gadeberg, C. C., Mouridsen, H. T., Jensen, M.-B., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710023371401 · Cited by 2,554
Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer
Ragaz, J., Jackson, S. M., Le, N., Plenderleith, I. H., Spinelli, J. J., Basco, V. E., Wilson, K. S., Knowling, M. A., Coppin, C. M. L., Paradis, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710023371402 · Cited by 1,745
Cheson, B. D., Cassileth, P. A., Head, D. R., Schiffer, C. A., Bennett, J. M., Bloomfield, C. D., Brunning, R., Gale, R. P., Grever, M. R., & Keating, M. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.5.813 · Cited by 770
Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast Cancer
Curtis, R. E., Boice, J. D., Stovall, M., Bernstein, L., Greenberg, R. S., Flannery, J. T., Schwartz, A. G., Weyer, P., Moloney, W. C., & Hoover, R. N. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262605 · Cited by 446
Rowley, J., Golomb, H., & Vardiman, J. (1981) · Blood · doi:10.1182/blood.v58.4.759.759 · Cited by 441
Fisher, B., Anderson, S., Wickerham, D. L., DeCillis, A., Dimitrov, N., Mamounas, E., Wolmark, N., Pugh, R., Atkins, J. N., Meyers, F. J., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1858 · Cited by 308
Self-citationPedersen-Bjergaard, J., Pedersen, M., Roulston, D., & Philip, P. (1995) · Blood · doi:10.1182/blood.v86.9.3542.bloodjournal8693542 · Cited by 306
Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure.
Levine, E. G., & Bloomfield, C. D. (1992) · PubMed · Cited by 301
Pedersen-Bjergaard, J., Philip, P., Larsen, S., Jensen, G., & Byrsting, K. (1990) · Blood · doi:10.1182/blood.v76.6.1083.1083 · Cited by 285
Fisher, B., Anderson, S., DeCillis, A., Dimitrov, N., Atkins, J. N., Fehrenbacher, L., Henry, P. H., Romond, E. H., Lanier, K. S., Davila, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3374 · Cited by 225
Self-citationRISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE
Pedersen-Bjergaard, J., Olesen Larsen, S., Struck, J., Hansen, H., Specht, L., Ersbøll, J., Hansen, M., & Nissen, N. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92744-9 · Cited by 218
Fisher, B., Rockette, H., Fisher, E. R., Wickerham, D. L., Redmond, C., & Brown, A. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.12.1640 · Cited by 204
Pedersen-Bjergaard, J., Philip, P., Larsen, S. O., Andersson, M. V., Daugaard, G., Ersbøll, J., Sw, H., HOU-JENSEN, K., Nielsen, D. L., & Sigsgaard, T. (1993) · PubMed · Cited by 181
Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia
Whitlock, J. A., Greer, J. P., & Lukens, J. N. (1991) · Cancer · doi:10.1002/1097-0142(19910801)68:3<600::aid-cncr2820680326>3.0.co;2-f · Cited by 170
Ratain, M. J., & Rowley, J. D. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058121 · Cited by 156
Obedian, E., FISCHER, D. B., & Haffty, B. G. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2406 · Cited by 148
Applications of crude incidence curves
Korn, E. L., & Dorey, F. J. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110611 · Cited by 132
Diamandidou, E., Buzdar, A. U., Smith, T. L., Frye, D., Witjaksono, M. A., & Hortobágyi, G. N. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2722 · Cited by 122
Andersen, M. K., Johansson, B., Larsen, S. O., & Pedersen-Bjergaard, J. (1998) · PubMed · Cited by 101
Tallman, M. S., Gray, R. P., Bennett, J. M., Variakojis, D., Robert, N. J., Wood, W. C., Rowe, J. M., & Wiernik, P. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1557 · Cited by 100
Haas, J., Kittelmann, B., Wh, M., et al. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.40 · Cited by 99
Osteosarcomas and adult soft tissue sarcomas: Is there a place for high LET radiation therapy?
Chauvel, P. (1992) · Annals of Oncology · doi:10.1093/annonc/3.suppl_2.s107 · Cited by 45
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Shallis, R. M., Wang, R., Davidoff, A., Ma, X., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.04.005 · Cited by 941
Lineage-Specific Hematopoietic Growth Factors
Kaushansky, K. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052706 · Cited by 509
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Panopoulos, A. D., & Watowich, S. S. (2008) · Cytokine · doi:10.1016/j.cyto.2008.03.002 · Cited by 394
Metadata
- Authors
- Smith, R. E., Bryant, J., DeCillis, A., & Anderson, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-04-01
- Volume
- 21
- Issue
- 7
- Pages
- 1195-1204
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2126964833
- Cited by
- 300
- References
- 27
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.